Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108LYoshiko Urata, Yoichi Nakanishi, Yasuo Iwamoto et al.|Journal of Clinical Oncology|2016Cited by 160
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trialTakehito Shukuya, Nobuyuki Yamamoto, Takeharu Yamanaka et al.|The Lancet Oncology|2015Cited by 86
Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L.Nobuyuki Katakami, Satoshi Morita, Hiroshige Yoshioka et al.|Journal of Clinical Oncology|2014Cited by 11
Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L.Takehito Shukuya, Nobuyuki Yamamoto, Takeharu Yamanaka et al.|Journal of Clinical Oncology|2015Cited by 4